Peter Petitt, Managing Director at Aon, and Foley & Lardner lawyers Lisa Conmy and Alidad Vakili engaged in an informative panel discussion on venture debt moderated by Bret Waters at 4thly Accelerator as part of the livestream for startup founders series hosted by 4thly and Foley.
The program covered when entrepreneurs can leverage debt from banks or non-bank lenders, how venture debt is structured, and the considerations.
The key takeaways were:
- Venture Debt comes in at the same time as or follows venture equity – best time to raise it is immediately after you raise equity, you have 12-18 months of runway and you can show recurring revenue streams.
- A company needs to have enough collateral, or something that can be used as collateral, such as intellectual property (IP), to consider a debt financing.
- Recurring revenue and IP are common sources of collateral in venture debt deals. Aon looks at IP – the world’s largest uninsured asset class and the world’s most undervalued asset class. A company’s IP portfolio is often its most valuable asset.
- We see companies securing a facility when times are good to enable them to extend runway before the next equity financing so that companies can raise in optimal conditions, and at a higher valuation than they would otherwise.
- It’s important to understand the covenants that are being requested and be careful of which ones align with the trajectory of the company.
- Warrants are a frequently requested sweetener in venture debt deals and are typically exercisable for common stock at a penny exercise price. Be careful of a penny exercise price if the warrants are exercisable for preferred stock.
Authors
Related Insights
08 December 2023
Foley Ignite
An Update on Reauthorizing the National Quantum Initiative
Signed into law in 2018, the goal of the National Quantum Initiative Act was “to accelerate quantum research and development for the economic and national security of the United States.”
08 December 2023
Innovative Technology Insights
FDA Approves Two Gene Therapies to Treat Sickle Cell Disease Including a CRISPR-Based Therapy
These new therapies harness the power of stem cells to help patients with sickle cell disease avoid vaso-oclusive events and crises.
08 December 2023
Foley Ignite
2024 Predictions: Unveiling the future of healthcare mergers and acquisitions
Foley & Lardner's Nathaniel Lacktman and Louis Lehot discuss which categories of digital health hold the most potential for M&As and why.